Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Harvoni

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Harvoni was produced by Bristol-Myers Squibb.

Torrid times at Gilead lead to calls for a major M&A deal

Torrid times at Gilead lead to calls for a major M&A deal Sales of its hepatitis drugs Sovaldi, Harvoni and Epclusa were down $1.5bn in the same period of 2015 to $3.3bn, with overall revenues down almost 10% to $7.5bn

Global pharma market forecast to reach $1.12tr by 2022

Global pharma market forecast to reach $1.12tr by 2022 Longtime market-leading products, such as Gilead Sciences' Harvoni (ledipasvir), which brought in $13.9bn last year, are predicted to lose their dominant positions in favour of newer therapies coming through

Merck & Co gets EU green light for hep C drug Zepatier

Merck & Co gets EU green light for hep C drug Zepatier Will enter a market currently dominated by Gilead's Harvoni and Sovaldi.  . ... The new drug launches into a market currently dominated by Gilead Sciences with its Harvoni (sofosbuvir/ledipasvir) combination and single-agent product Sovaldi (sofosbuvir)

Gilead’s hepatitis C sales start to slide – the question is how quickly?

Gilead’s hepatitis C sales start to slide – the question is how quickly? The US pharma company has reaped the benefits of stellar sales for its directly-acting HCV therapies since it first launched Sovaldi (sofosbuvir) in 2013 and two-drug follow-up Harvoni

European pharma ‘to grow 3.2% per year by 2022’

European pharma ‘to grow 3.2% per year by 2022’ In hepatitis C, Gilead's Sovaldi (2015: 1.443 bn; 2022: 609m) and its follow-up therapy Harvoni (2015: 2 bn; 2022: 887m) million) will struggle due to price pressure and

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics